AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21714844 — intervention group
Group type: COMPARATOR
Intervention: Usual staff development activities (Control group)
Number of subjects: 192
Study 21714844 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational nursing intervention
Number of subjects: 192
Study 18292424 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash group (photographed with a flash of light)
Number of subjects: 90
Study 18292424 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction group (photographed without a flash of light)
Number of subjects: 90
Study 18292424 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 18292424 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash group
Number of subjects: 90
Study 18292424 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction group
Number of subjects: 90
Study 17238666 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated prompts delivered via mobile devices to monitor exercise and symptoms
Number of subjects: 0
Study 17238666 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability of mobile devices for monitoring
Number of subjects: 0
Study 12897327 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/day
Number of subjects: 216
Study 12897327 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg/day
Number of subjects: 216
Study 12897327 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (250 mg or 500 mg daily)
Number of subjects: 216
Study 12897327 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 216
Study 11502792 — intervention group
Group type: COMPARATOR
Intervention: 0 mg oral androstenedione
Number of subjects: 37
Study 11502792 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral androstenedione
Number of subjects: 37
Study 11502792 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral androstenedione
Number of subjects: 37
Study 9132735 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-step Approach
Number of subjects: 73
Study 9132735 — intervention group
Group type: COMPARATOR
Intervention: Nonstrategy
Number of subjects: 73
Study 8321259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal chemotherapy during the first year; cranial irradiation and intrathecal chemotherapy one year after remission for high-risk patients
Number of subjects: 351
Study 8321259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal injections of chemotherapeutic agents and cranial irradiation for patients with central nervous system leukemia at diagnosis
Number of subjects: 351
Study 8321259 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cerebrospinal fluid blast cells with fewer than 5 leukocytes per microliter
Number of subjects: 351
Study 2455140 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine plus mefruside (1 q.d.)
Number of subjects: 24
Study 2455140 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine plus placebo
Number of subjects: 24
Study 29673356 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with fibromyalgia (FM)
Number of subjects: 118
Study 26813242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 25
Study 26813242 — intervention group
Group type: EXPERIMENTAL
Intervention: Conus attachments
Number of subjects: 25
Study 26813242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study 24755566 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Acupuncture (RA) + Time Method Acupuncture (TA)
Number of subjects: 60
Study 23349557 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of ALA after 10 days of oral ingestion (Group C)
Number of subjects: 30
Study 23349557 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of ALA (single dose) (Group B)
Number of subjects: 30
Study 23349557 — intervention group
Group type: COMPARATOR
Intervention: 90 dB HL 3 kHz pure tone for 10 min (Group A)
Number of subjects: 30
Study 21140562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin as a supporting drug in CAF chemotherapy
Number of subjects: 0
Study 21140562 — intervention group
Group type: COMPARATOR
Intervention: CAF chemotherapy
Number of subjects: 0
Study 17622283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence of 50 r.min-1
Number of subjects: 10
Study 17622283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence of 90 r.min-1
Number of subjects: 10
Study 17622283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence of 50 and 70 r.min-1
Number of subjects: 10
Study 15716608 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study 15716608 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 0
Study 11982877 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest tube placement
Number of subjects: 72
Study 11982877 — intervention group
Group type: COMPARATOR
Intervention: Venous catheter insertion
Number of subjects: 72
Study 11938852 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation plus surgery (RS)
Number of subjects: 370
Study 11938852 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (SA)
Number of subjects: 370
Study 11938852 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (SA) for stage III and IV supraglottic carcinomas
Number of subjects: 370
Study 11938852 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation plus surgery (RS) for stage III and IV supraglottic carcinomas
Number of subjects: 370
Study 11938852 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (SA) for T3 and T4 supraglottic carcinomas
Number of subjects: 370
Study 11938852 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation plus surgery (RS) for T3 and T4 supraglottic carcinomas
Number of subjects: 370
Study 7631729 — intervention group
Group type: EXPERIMENTAL
Intervention: Kelly plication
Number of subjects: 127
Study 7631729 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Pereyra needle suspension
Number of subjects: 127
Study 7631729 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch urethropexy
Number of subjects: 127
Study 1497046 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring and daily midwife contact
Number of subjects: 168
Study 1497046 — intervention group
Group type: COMPARATOR
Intervention: Standard care for high-risk women (control)
Number of subjects: 168
Study 350129 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine therapy
Number of subjects: 94
Study 350129 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine alone or added to stable dose of levodopa
Number of subjects: 94
Study 350129 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone or added to stable dose of amantadine
Number of subjects: 94
Study 350129 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of amantadine a day
Number of subjects: 94
Study 350129 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of amantadine a day
Number of subjects: 94
Study 350129 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 94
Study 350129 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 94
Study 28692703 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from faculty staff physicians
Number of subjects: 40
Study 28692703 — intervention group
Group type: COMPARATOR
Intervention: Feedback from patient instructors (PIs)
Number of subjects: 40
Study 26115203 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G‐GR) 1,800 mg once daily
Number of subjects: 719
Study 26115203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 719
Study 24118500 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised injectable heroin treatment
Number of subjects: 127
Study 24118500 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised injectable methadone treatment
Number of subjects: 127
Study 24118500 — intervention group
Group type: COMPARATOR
Intervention: Optimised oral methadone treatment
Number of subjects: 127
Study 21305524 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg plus MTX
Number of subjects: 1081
Study 21305524 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg plus MTX
Number of subjects: 1081
Study 21305524 — intervention group
Group type: COMPARATOR
Intervention: placebo plus MTX
Number of subjects: 1081
Study 19489188 — intervention group
Group type: EXPERIMENTAL
Intervention: New toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride as sodium monofluorophosphate (MFP)
Number of subjects: 80
Study 19489188 — intervention group
Group type: COMPARATOR
Intervention: Commercial sensitive toothpaste containing 2% potassium ion and 1450 ppm fluoride as sodium fluoride (NaF)
Number of subjects: 80
Study 17061598 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-injection thoracic paravertebral anesthesia (TPVA) with intravenous sedation
Number of subjects: 180
Study 17061598 — intervention group
Group type: COMPARATOR
Intervention: Traditional multicomponent general anesthesia
Number of subjects: 180
Study 16915030 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day irbesartan
Number of subjects: 14
Study 16915030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12820855 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional X-ray examination
Number of subjects: 47
Study 12820855 — intervention group
Group type: COMPARATOR
Intervention: Standard dose CT examination
Number of subjects: 47
Study 10366086 — intervention group
Group type: EXPERIMENTAL
Intervention: EXCIMER (193-nm Meditec excimer laser)
Number of subjects: 179
Study 10366086 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (hand-held motor trephine)
Number of subjects: 179
Study 7718370 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 110
Study 7718370 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injections (IMI)
Number of subjects: 110
Study 2045142 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Sodium (100 mmol sodium/day)
Number of subjects: 21
Study 2045142 — intervention group
Group type: COMPARATOR
Intervention: Slow Sodium placebo
Number of subjects: 21
Study 7257433 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole preoperative preparation
Number of subjects: 0
Study 31633313 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy low-fat diet
Number of subjects: 609
Study 31633313 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy low-carbohydrate diet
Number of subjects: 609
Study 28737425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual orthodontics (20 patients)
Number of subjects: 40
Study 28737425 — intervention group
Group type: COMPARATOR
Intervention: Conventional buccal orthodontics (20 patients)
Number of subjects: 40
Study 25592010 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) 150mg/kg
Number of subjects: 32
Study 25592010 — intervention group
Group type: COMPARATOR
Intervention: NaCl (control) 24mg/kg
Number of subjects: 32
Study 23598172 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily)
Number of subjects: 723
Study 23598172 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 723
Study 20975285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with high MPL content
Number of subjects: 80
Study 20975285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with lower MPL content
Number of subjects: 80
Study 20975285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18300905 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard open microsurgical discectomy (SOMD)
Number of subjects: 60
Study 18300905 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal access microsurgical discectomy (MAMD)
Number of subjects: 60
Study 17323729 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting of a specific area of the denture
Number of subjects: 14
Study 17323729 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14
Study 12867568 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high-dose steroids and nasal CPAP ventilation
Number of subjects: 190
Study 12867568 — intervention group
Group type: COMPARATOR
Intervention: Other three treatment groups (not specified)
Number of subjects: 190
Study 10711914 — intervention group
Group type: EXPERIMENTAL
Intervention: Program for relapse prevention (PRP)
Number of subjects: 82
Study 10711914 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 82
Study 8613546 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH-Ant 400 microgram/kg i.v.
Number of subjects: 0
Study 8613546 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 1343282 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg/day
Number of subjects: 20
Study 1343282 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril 30 mg/day
Number of subjects: 20
Study 6429694 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking during high-arousal situations
Number of subjects: 0
Study 6429694 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking in females
Number of subjects: 0
Study 6429694 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking in males
Number of subjects: 0
Study 6429694 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprivation in smokers
Number of subjects: 0
Study 6429694 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking in high-arousal situations
Number of subjects: 0
Study 6429694 — intervention group
Group type: COMPARATOR
Intervention: Smoking vs. nonsmokers
Number of subjects: 0
Study 31432074 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 21682
Study 31432074 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21682
Study 30508898 — intervention group
Group type: EXPERIMENTAL
Intervention: Funnel covered stents (44 cases)
Number of subjects: 88
Study 30508898 — intervention group
Group type: COMPARATOR
Intervention: Individualized stents (44 cases)
Number of subjects: 88
Study 27653814 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion 24 h after ticagrelor
Number of subjects: 44
Study 27653814 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion 48 h after ticagrelor
Number of subjects: 44
Study 27653814 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion 48 h after clopidogrel
Number of subjects: 44
Study 27653814 — intervention group
Group type: COMPARATOR
Intervention: No transfusion after clopidogrel
Number of subjects: 44
Study 24465156 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP (multi‐ingredient pre‐exercise workout supplement blend of creatine, betaine and a dendrobium extract)
Number of subjects: 43
Study 24465156 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP
Number of subjects: 43
Study 24465156 — intervention group
Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 43
Study 23093587 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 4680
Study 23093587 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary sodium-to-potassium ratio
Number of subjects: 4680
Study 23093587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary phosphorus
Number of subjects: 4680
Study 23093587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary magnesium
Number of subjects: 4680
Study 23093587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary iron
Number of subjects: 4680
Study 23093587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary thiamin
Number of subjects: 4680
Study 23093587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary folacin
Number of subjects: 4680
Study 23093587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary riboflavin
Number of subjects: 4680
Study 20733135 — intervention group
Group type: EXPERIMENTAL
Intervention: OGX-011 with docetaxel/prednisone (arm A)
Number of subjects: 82
Study 20733135 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel/prednisone without OGX-011 (arm B)
Number of subjects: 82
Study 18724865 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal therapy with or without the use of antibiotics
Number of subjects: 0
Study 18724865 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant therapy in subjects with diabetes
Number of subjects: 0
Study 18724865 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly controlled diabetes
Number of subjects: 0
Study 18724865 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled diabetes
Number of subjects: 0
Study 15842586 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Canrenoate (200 mg/day for 6 months)
Number of subjects: 22
Study 15842586 — intervention group
Group type: COMPARATOR
Intervention: No-drug treatment (control group)
Number of subjects: 22
Study 14699226 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg) and Ondansetron (4 mg)
Number of subjects: 120
Study 14699226 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg) and Metoclopramide (10 mg)
Number of subjects: 120
Study 14699226 — intervention group
Group type: COMPARATOR
Intervention: Saline I.V.
Number of subjects: 120
Study 12114161 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone consultation with digital images
Number of subjects: 12
Study 12114161 — intervention group
Group type: COMPARATOR
Intervention: Telephone consultation without digital images
Number of subjects: 12
Study 10629548 — intervention group
Group type: EXPERIMENTAL
Intervention: High eosinophil counts
Number of subjects: 584
Study 10629548 — intervention group
Group type: EXPERIMENTAL
Intervention: High mast cell counts
Number of subjects: 584
Study 10629548 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Dukes' stage
Number of subjects: 584
Study 10629548 — intervention group
Group type: EXPERIMENTAL
Intervention: High age
Number of subjects: 584
Study 7568634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol pretreatment
Number of subjects: 10
Study 7568634 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐fenfluramine (d‐FEN)
Number of subjects: 10
Study 2258632 — intervention group
Group type: EXPERIMENTAL
Intervention: Human fibroblast interferon (3 X 10(6) units)
Number of subjects: 80
Study 2258632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 2258632 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional interferon beta
Number of subjects: 80
Study 2258632 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta
Number of subjects: 80
Study 6455048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride, calcium, and calciferol
Number of subjects: 22
Study 6455048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29679659 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional contagion (leaders transmitting emotions to followers)
Number of subjects: 64
Study 29679659 — intervention group
Group type: COMPARATOR
Intervention: Emotional non‐contagion (followers imitating a facial image)
Number of subjects: 64
Study 29679659 — intervention group
Group type: EXPERIMENTAL
Intervention: High emotional contagion (HEC) group
Number of subjects: 64
Study 29679659 — intervention group
Group type: COMPARATOR
Intervention: Low emotional contagion (LEC) group
Number of subjects: 64
Study 28423407 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-mediated follow-up algorithm based on weekly self-scored patient symptoms
Number of subjects: 133
Study 28423407 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up with CT scans scheduled every three to six months
Number of subjects: 133
Study 25288513 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 48
Study 25288513 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 48
Study 25100773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage group
Number of subjects: 58
Study 25100773 — intervention group
Group type: COMPARATOR
Intervention: Control group (cold pack)
Number of subjects: 58
Study 25100773 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulse compression group
Number of subjects: 58
Study 22933800 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to the target with contiguous surround (unsegmented)
Number of subjects: 0
Study 22933800 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to the target with segmented surround (gap or phase offset)
Number of subjects: 0
Study 19208261 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month treadmill walking program
Number of subjects: 210
Study 19208261 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month treadmill walking program
Number of subjects: 210
Study 19208261 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 210
Study 17301652 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg ATP administered through a naso-intestinal tube
Number of subjects: 0
Study 17301652 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered through a naso-intestinal tube
Number of subjects: 0
Study 17301652 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no indomethacin or ATP/placebo)
Number of subjects: 0
Study 15110902 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg of slow-release indapamide SR
Number of subjects: 125
Study 15110902 — intervention group
Group type: COMPARATOR
Intervention: 5 mg of amlodipine
Number of subjects: 125
Study 15110902 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg of slow-release indapamide SR + 4 mg of perindopril
Number of subjects: 125
Study 15110902 — intervention group
Group type: COMPARATOR
Intervention: 5 mg of amlodipine + 4 mg of perindopril
Number of subjects: 125
Study 11244764 — intervention group
Group type: EXPERIMENTAL
Intervention: dopamine 2 mcg.kg‐1.min‐1
Number of subjects: 21
Study 11244764 — intervention group
Group type: EXPERIMENTAL
Intervention: dobutamine 2 mcg.kg‐1.min‐1
Number of subjects: 21
Study 11244764 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 21
Study 9547836 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-step sequence
Number of subjects: 48
Study 9547836 — intervention group
Group type: COMPARATOR
Intervention: 8-step sequence
Number of subjects: 48